Artelo Biosciences Inc (ARTL) - News Archive

: This article examines the recent developments surrounding Artelo Biosciences, Inc., focusing on the company’s encouraging interim Phase 2 results for the treatment of Cancer Anorexia-Cachexia Syndrome (CACS) utilizing...

The treatment of mood and anxiety disorders continues to present significant challenges, prompting ongoing research into novel therapeutic pathways. Traditional pharmacologic approaches, primarily selective serotonin re...

Artelo Biosciences: Navigating Financial Challenges Amid Promising Clinical DevelopmentsIntroductionArtelo Biosciences, Inc. (Nasdaq: ARTL) recently announced a private placement financing round that raised approximatel...

: Artelo Biosciences has announced significant findings from its Phase 1 clinical trial (CAReS) evaluating ART27.13, an investigational treatment for cancer-related anorexia. The results indicate a favorable safety prof...

Cutting-Edge Advances in Pain and Anxiety Management: Artelo Biosciences Groundbreaking Discoveries in Non-Opioid Treatments Artelo Biosciences, a trailblazer in the biopharmaceutical industry, continues to make signifi...

Artelo Biosciences Receives FDA Clearance for ART26.12: A Promising Breakthrough in Painful Neuropathies Treatment Addressing the Unmet Need in Painful NeuropathiesPainful neuropathies, such as chemotherapy-induced peri...

Artelo Biosciences recently presented a series of compelling preclinical studies on their investigational therapy, ART12.11, at the 34th Annual International Cannabinoid Research Society Symposium. The findings indicate...

Artelo Biosciences Presents Highly Encouraging Data Towards Developing a Solid Dosage Form of ART12.11 at CT-CANN24 Artelo Biosciences Inc., a leading biopharmaceutical company dedicated to the development and commercia...

:This article presents an in-depth review of Artelo Biosciences Inc. s recent peer-reviewed publication highlighting Fatty Acid Binding Protein 7 (FABP7) as a potential game-changer in cancer therapy and offers further...

Artelo Biosciences, a clinical-stage pharmaceutical company specializing in modulating lipid-signaling pathways, has recently published new pre-clinical research demonstrating the effectiveness of its asset, ART26.12, i...

In a landmark development, Artelo Biosciences, Inc. (Nasdaq:ARTL), a clinical-stage pharmaceutical company committed to the propagation of lipid-signaling pathways to cultivate treatments for cancer, neuropathic pain, a...